ADAR1 Capital Management »

Protagonist Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Protagonist Therapeutics (PTGX) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Protagonist Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Protagonist Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Protagonist Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $23M 786k 28.93
2023-12-31 $4.6M 201k 22.93

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Protagonist Therapeutics

BlackRock
Farallon Capital Management
BlackRock
Vanguard Group
Johnson & Johnson
State Street Corporation
Leucadia National Corporation
BVF
Pacer Advisors
Geode Capital Management
Perceptive Advisors
T. Rowe Price Associates
Kynam Capital Management
Invesco
Goldman Sachs Group

View all funds holding Protagonist Therapeutics